PSNL
Personalis, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -20.0% ·
share flow +5.6% ·
net new positions -20.0%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 68 | +6 | 44.71M | $598.60M | +11 | −5 |
| Q1 2026 | 65 | +1 | 39.38M | $250.81M | +9 | −8 |
| Q4 2025 | 64 | +1 | 35.38M | $281.65M | +2 | −1 |
| Q3 2025 | 13 | 0 | 21.61M | $140.91M | n/a | n/a |
| Q2 2025 | 10 | -1 | 19.31M | $126.70M | n/a | −1 |
| Q1 2025 | 8 | -2 | 10.69M | $37.54M | n/a | −2 |
| Q4 2024 | 10 | 0 | 10.13M | $58.56M | n/a | n/a |
| Q3 2024 | 9 | +1 | 11.64M | $62.64M | +2 | −1 |
| Q2 2024 | 8 | n/a | 8.68M | $10.16M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 7.19M | +6.1% | $25.23M | 0.3% | ▲ Add | 4 | SEC ↗ |
| 2 | Renaissance Technologies ✦ | 1.03M | +12.3% | $3.63M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Millennium Management ✦ | 871.51K | -33.8% | $3.06M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Marshall Wace ✦ | 696.29K | +894.5% | $2.44M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Geode Capital Management ✦ (passive) | 514.18K | +3.2% | $1.81M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 6 | State Street Global Advisors ✦ (passive) | 195.26K | -1.6% | $685,373 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 110.21K | -24.3% | $386,823 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 85.00K | -10.5% | $299,000 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Citadel Advisors | $572,376 | was 0.0% |
| Arrowstreet Capital | $66,366 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 140 holders, 84.04M shares, $493.33M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 4.00K sh · $64,848
Officer, Director · 7.46K sh · $120,985
Officer · 2.07K sh · $33,543
Officer · 2.93K sh · $47,541
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
12.5% of class · View original SEC filing ↗
2.0% of class · View original SEC filing ↗